House Committee requests EpiPen documents from Mylan

>

Mylan said earlier it would launch the first generic version of EpiPen for $300, half the price of the branded product, in the drugmaker's second step in less than a week to counter a backlash over the product's steep price.

Chaffetz and Cummings, the committee's chairman and ranking member respectively, requested documents related to Mylan's revenue from sales of EpiPens since 2007, manufacturing costs and the amount the company receives from federal health care programs. 

(Reporting by Ankur Banerjee in Bengaluru; Editing by Ted Kerr)